FDA review of drug names
This article was originally published in The Tan Sheet
Executive Summary
Drug Safety & Risk Management Advisory Committee will convene Dec. 4 to "discuss current screening methods to assess sound alike and look alike proprietary drug names, in order to reduce the incidence of medication errors." Meeting, previously scheduled for Sept. 18-19, was postponed for weather-related reasons. Session will follow-up on topics explored at a June meeting co-sponsored by FDA, PhRMA and the Institute for Safe Medication Practices (1"The Tan Sheet July 7, 2003, p. 12). Panel will meet at the Holiday Inn in Gaithersburg, from 8 am to 5 pm...
You may also be interested in...
Drug Names Tentatively Accepted As Trademarks Could Be Placed On Internet
FDA is thinking of making tentatively accepted drug trade names viewable on the Internet
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.